Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study

Nirmatrelvir-ritonavir is used in patients with coronavirus disease 2019 (COVID-19) with normal or mild renal impairment (eGFR ≥30 ml/min per 1.73 m2). There is limited data regarding its use in advanced kidney disease (eGFR

Saved in:
Bibliographic Details
Published in:EClinicalMedicine 2024-06, Vol.72, p.102620-102620, Article 102620
Main Authors: Chu, Wing Ming, Wan, Eric Yuk Fai, Ting Wong, Zoey Cho, Tam, Anthony Raymond, Kei Wong, Ian Chi, Yin Chan, Esther Wai, Ngai Hung, Ivan Fan
Format: Article
Language:English
Subjects:
Advanced kidney disease
CKD
Molnupiravir
Nirmatrelvir-ritonavir
Renal failure
SARS-CoV-2
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nirmatrelvir-ritonavir is used in patients with coronavirus disease 2019 (COVID-19) with normal or mild renal impairment (eGFR ≥30 ml/min per 1.73 m2). There is limited data regarding its use in advanced kidney disease (eGFR
ISSN:2589-5370
2589-5370
DOI:10.1016/j.eclinm.2024.102620